Valneva SE (VALN) has a near-term catalyst to watch related to its tetravalent Shigella vaccine candidate, S4V2, developed in partnership with LimmaTech Biologics.
Shigellosis, caused by Shigella bacteria, is the second leading cause of fatal diarrheal disease worldwide, responsible for an estimated 600,000 deaths annually, particularly among children in low-and middle-income countries. Despite this burden, no approved Shigella vaccine currently exists, making S4V2 the most clinically advanced candidate in development.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.